welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes
study id #: NCT02198092
condition: Familial Adenomatous Polyposis, Map Syndrome, Lynch Syndrome, HNPCC, Colorectal Cancer
This is an observational, case-control study evaluating the quantitative level of Septin9 in plasma pre- and post-colectomy in hereditary colorectal cancer (CRC) syndrome patients (Familial Adenomatous Polyposis (FAP), Lynch syndrome (also known as HNPCC), and Multiple Adenomatous Polyposis (MAP, also known as MYK/MYH) cases) and genetically related FAP-family members as controls and references.
intervention: Other: Epi proColon Testing
start date: July 2014
estimated completion: August 2019
last updated: August 28, 2019
size / enrollment: 24
study design: Observational Model: Case Control, Time Perspective: Prospective
- Septin9 Plasma Levels [ Time Frame: Up to 2 years ]
The primary objective of the study is the observational analysis of quantitative Septin9 plasma levels over time in hereditary CRC syndrome patients pre- and post-colectomy.
- Septin9 Plasma Levels Versus Polyps [ Time Frame: Up to 2 years ]
Correlation of quantitative Septin9 plasma levels with the approx. number of polyps
- Pre- and Post-Colectomy Colonic Epithelial Cell Numbers [ Time Frame: Up to 2 years ]
Correlation of circulating colonic epithelial cell number pre- and post-colectomy
- Septin9 Levels Versus Circulating Colonic Epithelial Cell Numbers [ Time Frame: Up to 2 years ]
Correlation of circulating colonic epithelial cell number with Septin9 levels
• Informed consent provided
• Age > or = to 18 years of age
• Patient group FAP
- Clinical diagnosis of familial adenomatous polyposis
• Patient group Lynch syndrome Clinical diagnosis of Lynch syndrome
• Patient group MAP
- Clinical diagnosis of MYH-associated polyposis and presence of more than 20 colon polyps
• Control group (FAP)
- Genetically related family member of patient
• Patients: Able and willing to attend routine follow-up as advised
• Controls, i.e. relatives of patients: Willingness to give blood at each routine follow-up as advised for the diseased relative
• Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV)
• Current diagnosis of colorectal cancer
sponsor: University of Pennsylvania
investigators: Bryson Katona, MD
trial center locations: United States
expertly curated content related to this topic
Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatou...Exisulind (sulindac sulfone; FGN-1), a m...
An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal SurgeryThis will be a prospective, multi-center...
Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps TrialOBJECTIVES: Subjects in the Prevention ...
Gliotoxin Inhibits Proliferation and Induces Apoptosis in Colorectal Cancer CellsThe discovery of new bioactive compounds...
Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous PolyposisA Phase 2, randomized, double blind, pla...
A Randomized Controlled Trial of Eicosapentaenoic acid and/or Aspirin For Colorectal Adenoma Prevention During Colon...BACKGROUND: The naturally-occurring ome...
Ileal Pouch-Anal Anastomosis RegistryLittle is known about the factors that p...